3 High-Yielding Dividend Stocks That Investors Can Safely Buy and Hold for Decades

The article recommends Clorox, Brookfield Renewable and Verizon as higher-yielding stocks amid concerns about expensive equities, persistent inflation and elevated interest rates. Their forward dividend yields are 5.7%, 5.4% and 6.3%, respectively; Brookfield expects distributions to grow 5%–9% annually, while Clorox forecasts fiscal-year organic revenue growth of 3.5%–4.5%. The outlook is income-focused, with limited growth potential noted for Verizon and a recent operational recovery described at Clorox.

Analysis

The common exposure here is duration, not simply “defensive” cash flow: higher real yields can compress dividend-stock multiples even if payouts hold. That creates a near-term headwind for all three and makes headline yield a poor entry signal without free-cash-flow coverage and balance-sheet checks.

Over 1–3 months, Clorox is the clearest operating-repair trade, but the thesis needs evidence that volume and gross margin recover—not just management’s organic-growth outlook. Its smaller scale versus Procter & Gamble leaves less room to absorb execution or input-cost shocks. A relative long CLX/short PG is only attractive if Clorox’s reported sell-through and margins improve while its valuation discount remains wide; absent valuation and current operating data, this is a watchlist setup, not a blind pair.

Brookfield Renewable’s asset-selection and recycling flexibility may create value, but its distribution-growth ambition is not the same as internally funded growth. Project returns, funding costs, currency exposure and dilution determine whether that flexibility benefits BEPC holders. Boralex could face a higher bar on capital returns as investors scrutinize acquired-asset economics; the direction is not established by the article.

Verizon’s mature customer base can support cash generation, but saturation limits growth optionality. Debt costs, network investment and competitive pricing can erode dividend coverage before the payout itself changes. Over 6–18 months, the key distinction is whether cash flow after capital spending covers distributions and debt obligations. Falsifiers: renewed CLX margin deterioration, BEPC funding-dependent distribution growth, VZ weaker post-capex free cash flow, or a sustained rise in real yields. The contrarian risk is treating a high yield as evidence of safety when it may partly reflect impaired growth or elevated financing risk.

Key Decisions for Investors

• Do not chase the yields solely on this article. Before adding, verify each company’s free-cash-flow payout coverage, debt maturities/refinancing costs and current valuation; these are missing inputs.
• Keep CLX on a conditional turnaround watchlist. Consider a relative CLX-versus-PG position only after Clorox shows improving volume and gross margins; exit the thesis if execution slips or the expected recovery fails to appear in reported results.
• If seeking renewable exposure, consider a staged BEPC position rather than underwriting its stated distribution-growth range. Require evidence that project funding and distributions are supported by operating cash flow; reassess on material dilution or weaker asset-level returns.
• Treat VZ primarily as an income and rate-risk position, not a growth holding. Track post-capex free cash flow and leverage; reduce exposure if dividend coverage weakens, particularly alongside higher real yields.